These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20640994)

  • 1. Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA.
    Borgen PO; Dahl OE; Reikeras O
    Hip Int; 2010; 20(3):301-7. PubMed ID: 20640994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis.
    Borgen PO; Dahl OE; Reikerås O
    Clin Orthop Relat Res; 2012 Sep; 470(9):2591-8. PubMed ID: 22476844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2199-207. PubMed ID: 10904464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    Francis CW; Pellegrini VD; Totterman S; Boyd AD; Marder VJ; Liebert KM; Stulberg BN; Ayers DC; Rosenberg A; Kessler C; Johanson NA
    J Bone Joint Surg Am; 1997 Sep; 79(9):1365-72. PubMed ID: 9314399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
    Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
    Lassen MR; Borris LC; Anderson BS; Jensen HP; Skejø Bro HP; Andersen G; Petersen AO; Siem P; Hørlyck E; Jensen BV; Thomsen PB; Hansen BR; Erin-Madsen J; Møller JC; Rotwitt L; Christensen F; Nielsen JB; Jørgensen PS; Paaske B; Tørholm C; Hvidt P; Jensen NK; Nielsen AB; Appelquist E; Tjalve E
    Thromb Res; 1998 Mar; 89(6):281-7. PubMed ID: 9669750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
    Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
    Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of dextran 70 and dalteparin does not increase perioperative blood loss compared to dextran 70 alone in major orthopedic surgery.
    Dahl OE; Walsoe HK; Aspelin T; Roise O; Arnesen H; Lyberg T
    Haemostasis; 1999; 29(5):262-8. PubMed ID: 10754378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment.
    Krasiński Z; Szpurek D; Staniszewski R; Dzieciuchowicz L; Pawlaczyk K; Krasińska B; Wójcicka K; Urbanek T
    Int Angiol; 2014 Aug; 33(4):365-71. PubMed ID: 25056168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
    Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
    Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar Clinical Outcomes with Preoperative and Postoperative Start of Thromboprophylaxis in THA: A Register-based Study.
    Borgen PO; Pripp AH; Dybvik E; Leistad L; Dahl OE; Reikerås O
    Clin Orthop Relat Res; 2017 Sep; 475(9):2245-2252. PubMed ID: 28643079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study.
    Tørholm C; Broeng L; Jørgensen PS; Bjerregaard P; Josephsen L; Jørgensen PK; Hagen K; Knudsen JB
    J Bone Joint Surg Br; 1991 May; 73(3):434-8. PubMed ID: 1670445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.
    Rasmussen MS; Jorgensen LN; Wille-Jørgensen P; Nielsen JD; Horn A; Mohn AC; Sømod L; Olsen B;
    J Thromb Haemost; 2006 Nov; 4(11):2384-90. PubMed ID: 16881934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
    Tincani E; Mannucci C; Casolari B; Turrini F; Crowther MA; Prisco D; Cenci AM; Bondi M
    Haematologica; 2006 Jul; 91(7):976-9. PubMed ID: 16757417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.